Abstract
Cardiotoxicity is the most dramatic complications of cancer therapies,
leading to halt in potentially life-saving anti-tumor treatment regimens
and a poor survival prognosis in a non-negligible percentage of
patients. Angiotensin converting enzyme inhibitors (ACEIs) and
β-blockers are effective in the treatment of the cancer therapy–related
cardiac dysfunction (CTRCD), while their roles in the prevention of
cardiotoxicity are unclear. Sacubitril/valsartan was advantageous over
ACEI in heart failure patients for further reduction of cardiovascular
death or heart failure re-hospitalization. However, there is short of
well-established testimony of its efficacy and safety in the prevention
and treatment of CTRCD in the cardio-oncology setting. Although some
small observational studies found a good performance of
sacubitril/valsartan in patients with CTRCD, large-scale prospective
clinical studies are required to confirm its excellent results. In this
paper, we review the potential benefit of sacubitril/valsartan in human
subjects with CTRCD.